Navigation Links
MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System

WAYNE, N.J., July 6, 2012 /PRNewswire/ -- Maquet Critical Care AB and MAQUET Medical Systems USA today issued the following update regarding its voluntary worldwide field correction for its C20, C30 and C40 FLOW-i Anesthesia Systems.  The recall was related to a software problem with the MAN/AUTO switch used for changing between manual and automatic ventilation modes.  The corrective action associated with this field correction included upgrading the affected systems' software as well as providing new corresponding user's manuals. The U.S. Food and Drug Administration (FDA) has classified this as a Class I recall. 

This action only affected FLOW-i Anesthesia Systems distributed between May 2010 and December 2011 and therefore, has no affect on the company's current product production, shipping or distribution processes.

In specific C20, C30 and C40 FLOW-i Anesthesia Systems, if the MAN/AUTO switch was not fully engaged in either an "ON" or "OFF position, but rather was placed in an "in- between position" for more than five seconds, a Technical Alarm TE 613 may have been generated.  Activation of the Technical Alarm TE 613 causes the system to remain in the original mode selected and does not switch the ventilation mode. To deactivate the Technical Alarm TE 613, the system must be restarted.

In February 2012, MAQUET Medical Systems, USA and Maquet Critical Care AB initiated a voluntary field correction of FLOW-i Anesthesia System, model number C30, in the US.  FLOW-i Anesthesia System model numbers C20, C30 and C40 were affected worldwide.

FDA defines Class I recalls as, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."

For additional information regarding this closed field correction, please contact the local MAQUET Technical Support Department.  For US Technical Support, call 1-888-627-8383 and press option 2, followed by option 1, Monday through Friday from 8:00 am-7:00 pm EST.

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at

FLOW-i is manufactured by Maquet Critical Care AB and distributed in the US by MAQUET Medical Systems USA.

About MAQUET  As a trusted partner for hospitals and clinicians since 1838, MAQUET is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. MAQUET develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/Cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation.

The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines.

MAQUET also equips Surgical Workplaces with critical infrastructure such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.

MAQUET is a subsidiary of the publicly listed Swedish Getinge Group. In 2011, MAQUET generated nearly 1.4 billion Euro which is more than half of the Group's annual revenue of 2.4 billion Euros. The Getinge Group has 13,000 employees worldwide, including around 6,000 MAQUET employees in 50 international sales and service organizations, as well as a network of more than 280 sales representatives. For more information please visit and

MAQUET – The Gold Standard

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes
2. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
7. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
8. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
9. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
10. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
11. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
Breaking Medicine Technology:
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
Breaking Medicine News(10 mins):